Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Accumulated Expenses (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Other Accumulated Expenses for 12 consecutive years, with $1.3 million as the latest value for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses rose 120.49% year-over-year to $1.3 million; the TTM value through Mar 2026 reached $1.3 million, up 120.49%, while the annual FY2025 figure was $721000.0, 71.26% up from the prior year.
  • Other Accumulated Expenses hit $1.3 million in Q1 2026 for Syndax Pharmaceuticals, up from $721000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.2 million in Q3 2022 and bottomed at $208000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $1.0 million, with a median of $703000.0 recorded in 2023.
  • Year-over-year, Other Accumulated Expenses skyrocketed 1594.68% in 2022 and then crashed 83.13% in 2023.
  • Syndax Pharmaceuticals' Other Accumulated Expenses stood at $604000.0 in 2022, then skyrocketed by 47.02% to $888000.0 in 2023, then tumbled by 52.59% to $421000.0 in 2024, then surged by 71.26% to $721000.0 in 2025, then skyrocketed by 76.14% to $1.3 million in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $1.3 million, $721000.0, and $595000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.